Ratings by Leerink Partners (Marc Goodman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/15/2024 | LENZ Therapeutics Inc | LENZ | New Coverage | Outperform (N/A) |
21.89 (15.92) |
-27.27% | Details | |
| 3/11/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Market Perform (Outperform) |
3.36 (1.95) |
-41.96% | Details | |
| 12/22/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Market Perform (Outperform) |
215.19 (329.83) |
53.27% | Details | |
| 10/6/2023 | Neurocrine Bio. | NBIX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2023 | Belite Bio, Inc, ADR | BLTE | New Coverage | Outperform (N/A) |
17.90 (37.00) |
106.7% | Details | |
| 7/24/2023 | Neurocrine Bio. | NBIX | Upgrade | Outperform (Market Perform) |
97.91 (140.09) |
43.08% | Details | |
| 6/12/2023 | Oculis Holding AG | OCS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2023 | Denali Therapeutics Inc. | DNLI | New Coverage | Outperform (N/A) |
31.47 (16.11) |
-48.81% | Details | |
| 1/24/2023 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Outperform (N/A) |
19.20 (39.61) |
106.3% | Details | |
| 11/15/2022 | Satsuma Pharmaceuticals | STSA | Downgrade | Market Perform (Outperform) |
4.05 (1.10) |
-72.84% | Details | |
| 10/10/2022 | Satsuma Pharmaceuticals | STSA | Upgrade | Outperform (Market Perform) |
5.36 (1.10) |
-79.48% | Details | |
| 9/8/2022 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2022 | Eliem Therapeutics Inc. | ELYM | Maintain | Outperform (N/A) |
|
Details | ||
| 7/14/2022 | Karuna Therapeutics Inc. | KRTX | New Coverage | Outperform (N/A) |
128.87 (329.83) |
155.94% | Details | |
| 5/11/2022 | Biohaven Pharmaceutical Holding | BHVN | Downgrade | Market Perform (Outperform) |
83.14 (39.61) |
-52.36% | Details | |
| 4/26/2022 | Opthea Ltd. | OPT | New Coverage | Outperform (N/A) |
5.71 (3.36) |
-41.16% | Details | |
| 4/25/2022 | Eliem Therapeutics Inc. | ELYM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | Gemini Therapeutics Inc. | GMTX | Downgrade | Market Perform (Outperform) |
1.40 (1.35) |
-3.57% | Details | |
| 11/23/2021 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/7/2021 | Eliem Therapeutics Inc. | ELYM | New Coverage | Outperform (N/A) |
27.56 (3.75) |
-86.39% | Details | |
| 7/28/2021 | Alkermes | ALKS | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/13/2021 | Graybug Vision | GRAY | Downgrade | Market Perform (Outperform) |
4.73 (5.50) |
16.28% | Details | |
| 3/12/2021 | Aldeyra Therapeutics | ALDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2021 | Graybug Vision | GRAY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/5/2020 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/2/2020 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/15/2020 | Marinus Pharmaceuticals | MRNS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2020 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/6/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2020 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2020 | Sage Therapeutics | SAGE | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/3/2020 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2020 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/6/2020 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2020 | Biogen | BIIB | New Coverage | Outperform (N/A) |
272.73 (193.18) |
-29.17% | Details | |
| 12/6/2019 | Sage Therapeutics | SAGE | Upgrade | Market Perform (Underperform) |
149.21 (12.95) |
-91.32% | Details | |
| 9/17/2019 | Alder Biopharm | ALDR | Downgrade | Market Perform (Outperform) |
10.06 (18.88) |
87.67% | Details | |
| 9/13/2019 | Acadia Pharmaceuticals | ACAD | Upgrade | Outperform (Market Perform) |
39.14 (16.74) |
-57.23% | Details | |
| 8/7/2019 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2019 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/18/2019 | Allergen | AGN | Downgrade | Market Perform (Outperform) |
164.26 (193.02) |
17.51% | Details | |
| 7/17/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2019 | Alder Biopharm | ALDR | New Coverage | Outperform (N/A) |
11.06 (10.06) |
-9.04% | Details | |
| 4/9/2019 | Zogenix, Inc. | ZGNX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/19/2019 | Vertex | VRTX | Downgrade | Market Perform (Outperform) |
188.09 (404.91) |
115.27% | Details | |
| 3/12/2019 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/7/2019 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2019 | AC Immune SA | ACIU | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2019 | Sage Therapeutics | SAGE | Maintain | Underperform (N/A) |
|
Details | ||
| 12/19/2018 | Allergen | AGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2018 | Zogenix, Inc. | ZGNX | New Coverage | Outperform (N/A) |
40.75 (26.68) |
-34.53% | Details | |
| 11/13/2018 | Adamas Pharmaceuticals | ADMS | New Coverage | Outperform (N/A) |
11.90 (8.22) |
-30.92% | Details | |
| 11/13/2018 | Allergen | AGN | New Coverage | Outperform (N/A) |
165.52 (164.26) |
-0.76% | Details | |
| 11/13/2018 | Vertex | VRTX | New Coverage | Outperform (N/A) |
180.55 (188.09) |
4.18% | Details | |
| 11/13/2018 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
356.66 (907.32) |
154.39% | Details | |
| 11/13/2018 | GW Pharma | GWPH | New Coverage | Outperform (N/A) |
137.87 (218.96) |
58.82% | Details | |
| 11/13/2018 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Outperform (N/A) |
38.92 (39.61) |
1.77% | Details | |
| 11/13/2018 | Sage Therapeutics | SAGE | New Coverage | Underperform (N/A) |
130.94 (149.21) |
13.95% | Details | |
| 11/13/2018 | AC Immune SA | ACIU | New Coverage | Outperform (N/A) |
8.73 (2.38) |
-72.74% | Details | |
| 11/13/2018 | Neurocrine Bio. | NBIX | New Coverage | Market Perform (N/A) |
105.41 (140.09) |
32.9% | Details | |
| 11/13/2018 | Alkermes | ALKS | New Coverage | Market Perform (N/A) |
37.67 (24.26) |
-35.6% | Details | |
| 11/13/2018 | Acadia Pharmaceuticals | ACAD | New Coverage | Market Perform (N/A) |
18.86 (39.14) |
107.53% | Details |
